This story was originally published on the Hematology Advisor The introduction of monoclonal antibodies and immunomodulators into earlier lines of therapy may improve progression-free survival (PFS) in patients with refractory multiple myeloma (MM), according to a study reanalyzing clinical data collected at the Winship Cancer Center at Emory University in Atlanta, Georgia. Results were published in Cancer....Continue Reading